AstraZeneca’s Camizestrant Clears India’s SEC Review The Story: AstraZeneca’s camizestrant has received a positive SEC recommendation in India for HR-positive, HER2-negative advanced breast cancer wit...
Key Highlights: Implications: AstraZeneca’s positive SEC recommendation could accelerate Etcamah’s entry into India’s emerging ESR1-mutated breast cancer segment without a local Phase III ...
Key Highlights: Implications: The approval broadens AstraZeneca’s trastuzumab deruxtecan franchise in India from later-line metastatic use into the earlier, potentially larger HER2-positiv...
Key Highlights: Implications: This approval moves Enhertu + Perjeta into the front line of HER2‑positive metastatic breast cancer care in India, displacing taxane + tra...
Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
Key Highlights: Implications: Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.&nb...
